Abstract:
The invention provides the use of an indole or indoline derivative of Formula, II or III: wherein the substituents are as described in the specification; in the manufacture of a medicament for the treatment or prophylaxis of obesity or for the reduction of food intake. The invention also relates to the use of indole or indoline derivatives of Formula I, II or III for improving the bodily appearance of a mammal by causing loss of weight, as well as cosmetic compositions containing said compounds.
Abstract:
The present invention relates to 2-(benzoylamino)benzoic acid derivatives of the formula (I), wherein the variants Ar, X and R are described in the specification. The said compounds modulate the activity of peroxisome proliferator-activated receptors (PPAR) α and/or γ, and are predicted to be useful in the treatment of metabolic diseases, e.g. type II diabetes.
Abstract:
Process for bulk autoclaving of polysaccharides, wherein the process includes: a) dissolving the polysaccharides in an aqueous solution and mixing until a homogeneous solution is obtained; b) filling the resulting solution in at least one container; c) placing the filled container(s) including the solution in an autoclave; d) placing a sensor in at least one of the containers; and e) autoclaving the filled containers.
Abstract:
A dispenser comprising at least two parallel, hollow cylinders (14, 16) for sup- plying different mutually reactive components to a mixing device (33) located downstream of said cylinders. The dispenser comprises a respective first piston moveable in each of the cylinders (14, 16) and displaceable by a piston rod (22, 24) connected to the respective piston. A means for actuating the pistons rods (22, 24) to perform a forward stroke of the pistons in their respective cylinders (14, 16) for dispensing an amount of said reactive components to the mixing device (33) comprises at least one rotatable member (38) biased in a rotational direction by a torsion spring, and at least one flexible string (42, 44) attached to the rotatable member (38) and to an element (26) connected to the piston rods (22, 24). A manually operable brake member (46, 50) is arranged to normally act on the rotatable member (38) to hold it still, but, when deactivated, adapted to release the rotatable member (38) thereby causing the pistons to dispense the reactive components to the mixing device (33).
Abstract:
The present invention relates to substituted sulfonamide compounds of the general formula (I), wherein P is sulfonamide or amide-substituted sulfonic acid, which compounds are potentially useful for the prophylaxis and treatment of medical conditions relating to obesity, type II diabetes and/or disorders of the central nervous system.
Abstract:
The invention concerns a method for identifying RNA-binding molecules, comprising the steps of: predicting the structure of an RNA-fragment by an in silico method, choosing a suitable predicted RNA-fragment, synthesizing the cDNA-fragment corresponding to the predicted RNA-fragment, inserting the cDNA-fragment in the upstream proximity of a reporter assay gene, which reporter assay gene produces a signal upon translation, thereby forming a reporter construct, and performing a reporter gene assay, which assay monitors the interaction between a molecule to be tested for RNA-binding and the RNA-fragment of the reporter construct. Furthermore, the invention relates to the use of specific RNA-fragments in the method of the invention.
Abstract:
The invention provides anakinra for use in the treatment of SARS-CoV-2 infection, in particular for treating or alleviating symptoms of respiratory distress and/or hyperinflammation in a patient. The treatment comprises administering to a patient in need thereof a daily dose of at least about 400 mg of anakinra.
Abstract:
A fusion protein is provided, comprising an antibody fragment having a biologic activity, said antibody fragment being selected from the group consisting of a Fab, a ScFv, a dAb, a VHH and a VNAR; and one or more half-life extending polypeptide moieties, each moiety comprising 2 to 136 units, with the proviso that said moiety or multiple moieties in total comprises 10 to 136 units, wherein each unit is independently selected from the group consisting of all amino acid sequences according to SEQ ID NO:1: X1-X2-X3-X4-X5-X6-D-X8-X9-X10-X11 (SEQ ID NO: 1) in which, independently: X1 is P or absent; X2 is V or absent; X3 is P or T; X4 is P or T; X5 is T or V; X6 is D, G or T; X8 is A, Q or S; X9 is E, G or K; X10 is A, E P or T; and X11 is A, P or T. The half-life extending polypeptide moiety has a generally unfolded conformation and provides a fusion protein with a large hydrodynamic radius that may avoid renal clearance. As a result, the biological half-life of the fusion protein is increased and the biological effect of the biologically active polypeptide may thus be prolonged.
Abstract:
A fusion protein is disclosed, comprising (i) a lysosomal polypeptide; and (ii) a polypeptide moiety comprising 2-68 units, each unit being independently selected from the group consisting of all amino acid sequences according to SEQ ID NO: 1 : in which, independently: X1 is P or absent; X2 is V or absent; X3 is P or T; X4 is P or T; X5 is T or V; X6 is D, G or T; X8 is A, Q or S; X9 is E, G or K; X10 is A, E P or T; and X11 is A, P or T. The fusion protein exhibits improved distribution to target tissue and is useful in enzyme replacement therapy of lysosomal storage disease.
Abstract:
The invention relates to a polypeptide capable of binding human complement component 5 (C5), said polypeptide comprising the amino acid sequence [ BM ]-[L2]-QSX 42 X 43 LLX 46 EAKKLX 52 X 53 X 54 Q wherein [ BM ] is a C5 bindingmotif; [L2] is an interconnecting loop; X 42 is selected from A and S; X 43 is selected from N and E; X 46 is selected from A, S and C; X 52 is selected from E, N and S; X 53 is selected from D, E and S, provided that X 53 is not D when X 52 is N; and X 54 is selected from A and S.